Roivant Sciences News - October 21, 2026
🟢 Roivant Sciences is trading 5% up today after brepocitinib met both Phase 3 primary endpoints
Roivant Sciences is trading at $36.68, up 5.04%, after brepocitinib met primary endpoints in both Phase 3 CLARITY trials for non-infectious uveitis. - At Week...
🟢 Roivant Sciences is trading 10.5% up in pre-market after brepocitinib met primary endpoints in both trials
Roivant Sciences is trading at $38.60, up 10.54%, after positive Phase 3 results for brepocitinib in non-infectious uveitis. - CLARITY-1 and CLARITY-2 met...
Roivant Announces Positive Phase 3 Trial Results for Brepocitinib in Non-Infectious Uveitis
Roivant Sciences and its subsidiary Priovant Therapeutics announced positive results from the Phase 3 CLARITY program for its drug, brepocitinib, in treating...
Roivant's Eye-Disease Drug Aces Two Late-Stage Trials — But Can a $27 Billion Biotech Keep Delivering Without Revenue?
Shares surged 7.6% to $37.56 as Roivant Sciences delivered dual Phase 3 wins this morning for its lead anti-inflammatory drug in a rare eye disease,...
🟢 Roivant Sciences is trading 7.6% up in pre-market after positive Phase 3 brepocitinib results
Roivant Sciences is trading at $37.56, up 7.56%, as its recent announcements are the clearest explanation for pre-market strength. - The company announced...